NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript

Jonathan Javitt: Well, we’ve already filed an investigational new drug application with the FDA for the use of NRX-101 in pain and received an enthusiastic response or response that we’ve seen is enthusiastic from the FDA Division of Anesthesia, analgesia and addiction products, which is a division that regulates pain products. Clearly, if the DoD trial is positive, that would be a critical piece of evidence, but additional randomized controlled trials with NRX-101 in its commercial presentation would be required. We’ve talked about some of the non-dilutive capital that’s available, not only through the NIH, but we would expect that the Department of Defense would want to continue development of this drug because there’s such an acute need within DoD and elsewhere for a non-addictive non-opioid pain medication.

And certainly, a major initiative in chronic pain would require a capital raise from NRX side. But we have ample belief that, that capital would be available in the face of a positive readout in the 200-person trial.

Stephen Willard: Thank you very much. Thank you, everyone. That’s all the time we have for questions tonight. We appreciate you joining us. I’m just talking about our journey, reaching these important milestones for the company over the coming months and look forward to your participation in future calls. This concludes the NRX Pharmaceuticals third quarter conference call. Thank you all for participating.

Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.